Mitokinin

Mitokinin is a discovery-stage biotechnology company that developed selective small-molecule activators of PINK1, a kinase implicated in mitochondrial quality control and Parkinson's disease pathology. The company's lead compound is designed to address mitochondrial dysfunction believed to underlie neurodegeneration in Parkinson's disease, with the goal of creating a disease-modifying treatment rather than merely symptomatic relief. Mitokinin received over $1 million in grants from the Michael J. Fox Foundation and in October 2023 was acquired by AbbVie for over $650 million, further strengthening AbbVie's neuroscience pipeline.